

PERSONAL INFORMATION

Johann Lodewijk Hillege

WORK EXPERIENCE

- 1983- 1990 **Lecturer anatomy, physiology, first aid and hygiene**
Municipality of Leeuwarden (Netherlands)
Lecturer
- 1989- 1995 **Clinical research physician**
Department of Cardiology, University Hospital Groningen, Hanzeplein 1, 9700 RB Groninge (Netherlands)
Research Physician
- 1995- 1997 **Projectleader coronary and endovascular stents**
Cordis Europa NV, Oosteinde 8, 9301LJ Roden (Netherlands)
Project leader clinical evaluations
- 1997- 1998 **Director Endovascular**
Cordis Europa NV, Oosteinde 8, 9301LJ Roden (Netherlands)
Member of the management board, head of the clinical evaluation of medical devices
- 1998- 2001 **Department of Clinical Pharmacology**
University of Groningen, Broerstraat 5, 9700 AB, Groningen (Netherlands)
Lecturer
- 1998- Present **Clinical assessor**
Dutch Medicines Evaluation Board, Graadt van Roggenweg 500 3531 AH Utrecht (Netherlands)
Clinical regulatory assessment of medicines and devices
- 2001- 2013 **Clinical research**
Trial Coordination Centre, University Hospital Groningen, Hanzeplein 1, 9700 RB Groningen (Netherlands)
Director, general management
- 2004- 2007 **Assistant professor**
Department of Cardiology, University Hospital Groningen, Hanzeplein 1, 9700 RB Groningen (Netherlands)
Clinical research
- 2007- Present **Professor**
Department of Cardiology, University Hospital Groningen, Hanzeplein 1, 9700 RB Groningen (Netherlands)
Clinical research/teaching
- September 2013-September 2016 **Alternate CHMP member**
Dutch Medicines Evaluation Board (Netherlands)
Clinical regulatory assessment of medicines
- September 2016- Present **CHMP member**
Dutch Medicines Evaluation Board (Netherlands)

EDUCATION AND TRAINING

- 1978- 1982 **Teacher in Physical Education**
Academy of physical education, Groningen (Netherlands)

	Teaching
1982- 1990	Medical doctor University of Groningen, Medical Faculty, Broerstraat 5, 9700 AB, Groningen (Netherlands) Medical doctor
1990- 1992	Statistical analyst Netherlands Society for Statistics and Operation Research (Netherlands) Statistical analyst
1998- 2002	PhD University of Groningen, Department of Clinical Pharmacology, Broerstraat 5, 9700 AB, Groningen (Netherlands) Thesis Renal risk markers in cardiovascular disease
1991- 1993	Master of Science in Epidemiology Netherlands Epidemiological Society (Netherlands) Master of science
2019- Present	Epidemiology Scientific Researcher (Epidemiologist B) Stichting ter bevordering en instandhouding voor een stelsel van opleidingen tot Medisch-Biologisch Wetenschappelijk Onderzoeker (Netherlands)

ADDITIONAL INFORMATION

Expertise	Regulatory Clinical assessment of medicines and devices Cardiology Nephrology Epidemiology and statistics Clinical Pharmacology
Publications	Selected peer-reviewed publications - > 400 publications and contribution to book chapters - Web of Knowledge h-index: > 70 (Hillege OR Hillege) - Average impact factor of my publications: > 2 - Examples of some publications: Individual Trade-Offs Between Possible Benefits and Risks of Cancer Treatments: Results from a Stated Preference Study with Patients with Multiple Myeloma. Postmus D, Richard S, Bere N, van Valkenhoef G, Galinsky J, Low E, Moulon I, Mavris M, Salmonsson T, Flores B, Hillege H, Pignatti F. <i>Oncologist</i> . 2017 Oct 27. pii: theoncologist.2017-0257. Structured Frameworks to Increase the Transparency of the Assessment of Benefits and Risks of Medicines: Current Status and Possible Future Directions. Pignatti F, Ashby D, Brass EP, Eichler HG, Frey P, Hillege HL, Hori A, Levitan B, Liberti L, Lofstedt RE, McAuslane N, Micallef A, Noel RA, Postmus D, Renn O, Sabourin BJ, Salmonson T, Walker S. <i>Clin Pharmacol Ther</i> . 2015 Nov;98(5):522-33 Do European Patients Have a Shared Preference For The Benefits And Risks Of Medicines? Beyer A, Kingma B, Hoekstra T, Fasolo B, Hillege JL. <i>Value Health</i> . 2015 Nov;18(7) Risk attitudes and personality traits predict perceptions of benefits and risks for medicinal products: a field study of European medical assessors. Beyer AR, Fasolo B, de Graeff PA, Hillege HL. <i>Value Health</i> . 2015 Jan;18(1):91-9 Risk Perception of Prescription Drugs: Results of a survey among experts in the European Regulatory Network Beyer A, Fasolo B, Phillips LD, de Graeff PA, Hillege HL. <i>Med Decis Making</i> . 2013 May;33(4):579-92. Brain Natriuretic Peptide and Prognosis in Heart Failure Patients with Preserved and Reduced Ejection Fraction van Veldhuisen DJ, Linszen GCM, Jaarsma T, van Gilst WH, Hoes AW, Tijssen JGP, Paulus WJ, Voors AA, Hillege HL. <i>J Am Coll Cardiol</i> . 2013 Apr 9;61(14):1498-506 Postmus D, van Veldhuisen DJ, Jaarsma T, Luttik ML, Lassus J, Mebazaa A, Nieminen MS, Harjola VP, Lewsey J, Buskens E, Hillege HL. The COACH risk engine: a multistate model for predicting survival and hospitalization in patients with heart failure. <i>Eur J Heart Fail</i> . 2012 Feb;14(2):168-75.

de Boer RA, Schrotten NF, Bakker SJ, Mahmud H, Szymanski MK, van der Harst P, Gansevoort RT, van Veldhuisen DJ, van Gilst WH, Hillege HL. Plasma renin and outcome in the community: data from PREVEND. Eur Heart J. 2012 Sep;33(18):2351-9.

- Projects**
- 2002 - De Cock Foundation - Pathophysiological relationships and prognostic properties of increased levels of urinary albumin excretion in heart failure
 - 2006 - The Netherlands Heart Foundation - Progressive loss of renal function and its cardiac-hemodynamic and neurohormonal determinants in heart failure patients; a time course study
 - 2006 - Zesde Kaderprogramma - Workpackage leader in Applied Genomic Strategies for treatment and the prevention of cardiovascular death in uremia and end-stage renal disease project.
 - 2006 - Ti Pharma - Workpackage leader in The Escher Project: Science driven drug regulation and innovative research throughout phased drug development
 - 2008 - Workpackage leader in the Triumph project, translational Initiative on Unique and novel strategies for Management of Patients with Heart failure
 - 2008 - Principal investigator ARIANA-CHF-RD, a double-blind, placebo-controlled, investigator initiated, randomized trial investigating the safety and efficacy of additive renin inhibition with aliskiren on renal blood flow and neurohormonal activation in patients with chronic Heart failure and renal dysfunction
 - 2009- In-Touch. The INTOUCH study is a VWS sponsored study investigating the added value of Telecare and disease management in patients with severe heart failure.
 - 2010 - Workpackage leader in Bioshare-eU FP7-HEALTH . Biobank Standardisation and Harmonisation for Research Excellence in the European Union
 - 2010 - The Netherlands Heart Foundation - Prognostic properties of temporal changes in electrocardiograms
 - 2010 - Workpackage leader BIOSTAT-CHF FP7-HEALTH A systems BIOlogy Study to Tailored Treatment in Chronic Heart Failure
 - 2013 - Extension of the IMI Protect Work Package 6
 - 2014 - Get Real IMI
 - 2016 - ReConnect Dutch Heart Foundation
 - 2017 - Get Real IMI extension call

- Memberships**
- European Society of Cardiology
 - European Working Group of Heart Failure

Other Relevant Information